The Sanofi, Amgen, Alphabet, Novartis and PPD-backed clinical trials software producer is joining forces with publicly listed LifeSci Acquisition II Corp.

Kaiser Permanente has helped the parent company of in vitro diagnostics test provider ET Healthcare and biotechnology developer Gator Bio close its latest round.

The Fosun-backed gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

Lilly Asia Ventures was among the investors in a series B round for the renal disease treatment developer, which it incubated in 2018.

The genome sequencing technology provider has boosted its total funding to approximately $124m, Sinopharm and China General Technology Group having backed a $38.7m round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.

China Life Healthcare Fund and Venus Medtech have taken part in a round for the heart valve treatment developer sized in the hundreds of millions of dollars.

The Takeda and Access Industries-backed oncology therapeutics developer is targeting an offering on the Nasdaq Global Market having previously raised $190m.